Skip to main content

Outlook Therapeutics, Inc.

OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649989

In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Outlook Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of OTLK: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders5765+8
Shares7.56M8.50M+936.8K (+12.4%)
Value$90.0M$62.7M−$27.3M (−30.3%)

New holders (15)

Institutions that held Outlook Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to OTLK in Q2 2024
InstitutionSharesValue% of portfolio
Altium Capital Management LP501,785$3.70M1.53%
Boothbay Fund Management, LLC250,000$1.84M0.06%
Woodline Partners LP150,786$1.11M0.01%
LVW Advisors, LLC47,730$352.2K0.05%
Nuveen Asset Management, LLC45,881$338.6K0.00%
Susquehanna Fundamental Investments, LLC41,020$302.7K0.01%
UBS Oconnor LLC36,000$265.7K0.01%
Squarepoint Ops LLC31,388$231.6K0.00%
Susquehanna International Group, LLP15,678$115.7K0.00%
AQR Capital Management LLC10,164$75.0K0.00%
Corebridge Financial, Inc.4,235$31.3K0.00%
Mirae Asset Global ETFs Holdings Ltd.3,254$24.0K0.00%
Nisa Investment Advisors, LLC2,318$17.1K0.00%
Comerica Bank488$3.60K0.00%
Simplex Trading, LLC410$3.00K0.00%

Sold out (7)

Institutions that held Outlook Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of OTLK in Q2 2024
InstitutionShares, Q1 2024Value, Q1 2024
Armistice Capital, LLC714,285$8.53M
HRT Financial LP28,623$341.0K
Millennium Management LLC27,744$331.3K
Virtu Financial LLC18,213$217.0K
Renaissance Technologies LLC17,600$210.0K
American International Group, Inc.3,873$46.2K
Nelson, Van Denburg & Campbell Wealth Management Group, LLC1$11